Navigation Links
Clarient Reports 2009 Third Quarter; Nine Month Results
Date:11/3/2009

September 30, September 30, 2009 2008(*) 2009 2008(*) Net revenue $21,425 $18,997 $68,347 $51,799 Cost of services 9,796 8,596 28,675 24,465 ----- ----- ------ ------ Gross profit 11,629 10,401 39,672 27,334 Operating expenses: Sales and marketing 4,194 2,634 13,116 7,664 General and administrative 6,030 3,377 17,074 13,289 Bad debt 4,214 4,107 9,483 7,734 Research and development 282 98 805 321 --- --- --- --- Total operating expenses 14,720 10,216 40,478 29,008 ------ ------ ------ ------ Income (loss) from operations (3,091) 185 (806) (1,674) ------ --- ---- ------ Interest expense, net 144 2,399 4,056 5,747 --- ----- ----- ----- Loss from continuing operations before income taxes (3,235) (2,214) (4,862) (7,421) Income tax benefit (expense) - - 599 (6) Income from discontinued operations, net of income taxes - - 901 - --- --- --- --- Net loss (3,235) (2,214) (3,362) (7,427) Series A preferred stock beneficial conversion feature - - (4,290) -
'/>"/>
SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
2. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
3. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
4. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. Jim Agnello to Resign as Clarient Chief Financial Officer
8. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
9. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
10. Clarient to Commercialize Novel Breast Cancer Profile
11. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...24 Blue Marble Energy Corp. announ...evelopment Authority (OPDA) were recently awarded ...c Revitalization Board (CERB) in a private/public ...ty biochemical biorefinery in Lincoln County, WA. ...the development of our biorefinery and bring over ...
(Date:11/24/2009)...efficacy endpoint has been met for patients with a... , QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall...Z) (the "Company"), a global biopharmaceutical com...day announced positive efficacy data from a Phase ...ate, AEZS-108 (formerly AN-152), in patients with ...
(Date:11/24/2009)...ovember 24 Shire plc (LS...pharmaceutical company, today,announced that it ha... for,velaglucerase alfa, the company,s enzyme repl...f Type 1 Gaucher disease. This is the third market...en submitted, with previous,submissions in the Uni...
(Date:11/24/2009)..., Calif., Nov. 24 Genomi...at Randy Scott, Genomic Health,s Executive Chairma...ealth Care Conference in New York City on Tuesday,...ss the live and subsequently archived webcast of t...ion of Genomic Health,s website at http://investo...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Genomic Health to Present at Piper Jaffray Health Care Conference 2
...sed by the Elderly and Patients With Movement Diso...ngs , , HAIFA, Israel, May 18 Millions of people... their ability to walk. For many of them, traditio...isappointing substitute for being able to walk nor...igh-tech yet easy-to-use gait-training device, the...
...NTA, May 18 /PRNewswire-Asia/ -- Global biomedical...ion in Singapore in the year 2008. This rides on,S...omedical sciences R&D,expenditure exceeding US...ce in Singapore points to the city-state,s,attract...he fast growing Asian,market to fuel their growth....
...javik, ICELAND, May 17 In a paper published,today...sts from deCODE,genetics (Nasdaq: DCGN ) and acad...erlands present the discovery of single letter var... that influence the age of girls at menarche, the,...nfluenced by both genetic,and environmental factor...
Other Biology Technology:Now Available: State-of-the-Art Gait Training Device to Help Millions Walk More Normally Again 2Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 2Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 3Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 4Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 5deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease 2deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease 3deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease 4
(Date:11/25/2009)...niversity assistant professors recently received f...to continue research beneficial to understanding t..., Christopher Blackwood, assistant professor in t...grants to support two separate research projects. ...ecomposer Communities and Functions from the Leaf ...
(Date:11/24/2009)... years it has been prescribed by traditional heale...daches and stomach pain to fever and flu. , Now f...sity have been able to scientifically prove the pa...wise known as Brazilian mint. , Testing this anci...esearcher Graciela Rocha was able to show that whe...
(Date:11/24/2009)...s opening new doors to understanding how sounds as...of a marine mammal or if they hear it at all. , ...nners that NASA uses to detect flaws in the space ...ing scientists to peek inside the giant head of a ...nsional replicas of a whale,s hearing anatomy usin...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2Got a pain? -- Have a cup of Brazilian mint 2Rocket science leads to new whale discovery 2Reflective film can boost profits for apple growers 10621 1Reflective film can boost profits for apple growers 10621 2Sustainably grown garlic 10616 1Sustainably grown garlic 10616 2Sustainably grown garlic 10616 3Trauma Deadlier for Kids Without Insurance 60632 1Trauma Deadlier for Kids Without Insurance 60632 2
... Calif. (March 9, 2009)A minimally invasive interv...ively uses oxygen/ozone to relieve the pain of her...tes in the next few years, predict researchers at ...ual Scientific Meeting. In a related study, the in...relieves the pain associated with herniated disks....
...he largest study of its kind to evaluate the effec...oncludes that both are equal offenders when it com...f the study, led by researchers at Fred Hutchinson...ch issue of Cancer Epidemiology, Biomarkers and P...ed wine,s effects on breast-cancer risk. There is ...
...500,000 snippets of human DNA put scientists from ...ic variant on chromosome 8 occurs with significan...palate than in the control group. The results are ...urnal Nature Genetics . , Cleft lips and palates... One in about 700 babies in Central Europe are aff...
Other Biology News:Oh, my aching back: Give me a shot of ozone 2Oh, my aching back: Give me a shot of ozone 3Red wine vs. white? It makes no difference when it comes to breast-cancer risk 2Cleft lip and palate: Genes more important than thought? 2
...bus is a flexible, fully automated microplate stri...to its fully automated microplate strip washing ca...ith excellent performance and ease of operation. ...de manifolds of 8, 12 or 16 channels, crosswise as...
...Label Transfer Sulfo SBED Protein:Protein Interact...Transfer has rapidly gained traction as an in vitr...ing number of publications feature the exclusive P...agent to study a variety of issues relating to pro...
... Incubator is a compact benchtop and stackable mul...ntroller with a large display screen to accurately...ulation inside to evenly distribute temperature in...ed from the microprocessor controller. Built in ma...
Human siTrio from B-Bridge International
Biology Products: